Literature DB >> 17362805

Treating depression in the medically ill.

Dan V Iosifescu1.   

Abstract

Depression frequently is comorbid with a variety of medical illnesses; individuals who have such comorbidities may have increased morbidity and lower functional status. Usual antidepressant treatments can be effective in depressed patients who have comorbid medical illness. These patients, however, experience lower rates of recovery and remission of depressive symptoms and higher rates of relapse during follow-up than seen in patients who have MDD with no medical comorbidity. Comorbid medical illness therefore is a marker of treatment resistance in MDD. Collaborative treatments combining antidepressants, psychotherapy, education, and case management may be effective and could overcome the risk of treatment resistance. Two clinical strategies seem warranted in light of the studies presented here: (1) an increased index of suspicion for depression in medically ill patients, and (2) more intensive antidepressant treatment in depressed patients who have medical comorbidity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17362805     DOI: 10.1016/j.psc.2006.12.008

Source DB:  PubMed          Journal:  Psychiatr Clin North Am        ISSN: 0193-953X


  13 in total

1.  Depressive phenotypes evoked by experimental diabetes are reversed by insulin.

Authors:  Nancy Ho; Darrick T Balu; Monica R F Hilario; Julie A Blendy; Irwin Lucki
Journal:  Physiol Behav       Date:  2011-09-10

2.  Combined exercise and cognitive behavioral therapy improves outcomes in patients with heart failure.

Authors:  Rebecca A Gary; Sandra B Dunbar; Melinda K Higgins; Dominique L Musselman; Andrew L Smith
Journal:  J Psychosom Res       Date:  2010-03-12       Impact factor: 3.006

3.  Inflammatory biomarkers in depression: an opportunity for novel therapeutic interventions.

Authors:  Madeline Li; Joanna K Soczynska; Sidney H Kennedy
Journal:  Curr Psychiatry Rep       Date:  2011-10       Impact factor: 5.285

4.  Sertraline for Major Depression During the Year Following Traumatic Brain Injury: A Randomized Controlled Trial.

Authors:  Jesse R Fann; Charles H Bombardier; Nancy Temkin; Peter Esselman; Catherine Warms; Jason Barber; Sureyya Dikmen
Journal:  J Head Trauma Rehabil       Date:  2017 Sep/Oct       Impact factor: 2.710

5.  A randomized controlled trial of venlafaxine XR for major depressive disorder after spinal cord injury: Methods and lessons learned.

Authors:  Charles H Bombardier; Jesse R Fann; Catherine S Wilson; Allen W Heinemann; J Scott Richards; Ann Marie Warren; Larry Brooks; Catherine A Warms; Nancy R Temkin; Denise G Tate
Journal:  J Spinal Cord Med       Date:  2013-11-26       Impact factor: 1.985

6.  Olanzapine and fluoxetine combination therapy for treatment-resistant depression: review of efficacy, safety, and study design issues.

Authors:  William V Bobo; Richard C Shelton
Journal:  Neuropsychiatr Dis Treat       Date:  2009-07-02       Impact factor: 2.570

Review 7.  Effects of diabetes on hippocampal neurogenesis: links to cognition and depression.

Authors:  Nancy Ho; Marilyn S Sommers; Irwin Lucki
Journal:  Neurosci Biobehav Rev       Date:  2013-05-13       Impact factor: 8.989

8.  Association of treatment modality for depression and burden of comorbid chronic illness in a nationally representative sample in the United States.

Authors:  Danielle F Loeb; Vahram Ghushchyan; Amy G Huebschmann; Ingrid E Lobo; Elizabeth A Bayliss
Journal:  Gen Hosp Psychiatry       Date:  2012 Nov-Dec       Impact factor: 3.238

9.  Telephone and in-person cognitive behavioral therapy for major depression after traumatic brain injury: a randomized controlled trial.

Authors:  Jesse R Fann; Charles H Bombardier; Steven Vannoy; Joshua Dyer; Evette Ludman; Sureyya Dikmen; Kenneth Marshall; Jason Barber; Nancy Temkin
Journal:  J Neurotrauma       Date:  2015-01-01       Impact factor: 5.269

Review 10.  Incomplete remission in depression: role of psychiatric and somatic comorbidity.

Authors:  Christian Otte
Journal:  Dialogues Clin Neurosci       Date:  2008       Impact factor: 5.986

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.